New guidelines group the 12 available advanced treatments based on efficacy to help simplify decision-making processes for gastroenterologists, according to a Nov. 15 press release.
The AGA has categorized drugs with similar efficacy into “efficacy buckets,” allowing clinicians to break down effective treatments based on the likelihood of inducing remission.
Treatment recommendations include:
1. For patients with moderate-to-severe ulcerative colitis, start with advanced therapies and/or immunomodulators, rather than a step-up approach.
2. For patients who have not previously received advanced therapies, the medications with the highest efficacy include infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab and guselkumab.
3. For patients with prior exposure to advanced therapies, the medications with the highest efficacy include tofacitinib, upadacitinib and ustekinumab.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.